|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Operating expenses: | ||
| Research and development | ||
| General and administrative | ||
| Total operating expenses | ||
| Loss from operations | ||
| Other income (expense): | ||
| Change in estimated fair value of warrant liability | ||
| Gain on settlement of warrants | ||
| Loss on issuance of related party convertible notes payable at fair value | ||
| Change in estimated fair value of related party convertible notes payable | ||
| Interest expense | ||
| Interest income | ||
| Total other income (expense), net | ||
| Net loss | ||
| Weighted-average shares of common stock outstanding, basic | ||
| Weighted-average shares of common stock outstanding, diluted | ||
| Net loss per share attributable to common stockholders, basic | ||
| Net loss per share attributable to common stockholders, diluted |
Loading...
